Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Suppremol Gets Zambon Backing

December 12, 2005 | A version of this story appeared in Volume 83, Issue 50

SuppreMol, a spin-off of Germany's Max-Planck Institute of Biochemistry, has been launched with the backing of Z-Cube, the venture-capital arm of the Italian drugmaker Zambon. SuppreMol is developing drugs that treat autoimmune diseases and allergies by acting on Fc receptors. Z-Cube says SuppreMol is the first European company it has helped launch. "To our knowledge, this is the first financing of a biotech start-up in Germany this year," adds SuppreMol CEO Peter Buckel.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.